Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05433337 · ClinicalTrials.gov registry record · NA

Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study

A NA study of Fibromyalgia, sponsored by Swing Therapeutics.

Completed
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05433337: Completed NA study of Fibromyalgia, sponsored by Swing Therapeutics.

NCT05433337 is a NA study of Fibromyalgia that has completed, run by Swing Therapeutics. The registered enrollment target is 60 participants, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05433337, a NA study of Fibromyalgia, has completed, sponsored by Swing Therapeutics.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This study is designed as a 9-month extension of the original study (PROSPER-FM). The purpose of the extension study is to assess the long-term (up to 1 year) response to a digital therapy in the treatment of fibromyalgia.

Primary Outcome

PGIC scores included are: Very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse

Conditions Studied

Interventions

  • DEVICE Digital ACT

Study Locations (1)

California

  • Swing Therapeutics - San Francisco

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-06-08
Est. Completion 2024-03-05
Phase NA
Swing Therapeutics

6 total trials

What the finished NCT05433337 record still lists

NCT05433337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 178-participant average among 76 other Fibromyalgia trials with a reported enrollment target (66% lower).

The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 1 intervention - of which Digital ACT is the first listed.

NCT05433337 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05433337 about?

NCT05433337 is a clinical study titled "Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study". This study is designed as a 9-month extension of the original study (PROSPER-FM). The purpose of the extension study is to assess the long-term (up to 1 year) response to a digital therapy in the treatment of fibromyalgia.

What is the current status of trial NCT05433337?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2022-06-08. Estimated completion is 2024-03-05.

What conditions does trial NCT05433337 study?

This clinical trial studies the following conditions: Fibromyalgia.

What interventions are being tested in trial NCT05433337?

The interventions under investigation include: Digital ACT (DEVICE).

Who is sponsoring clinical trial NCT05433337?

This trial is sponsored by Swing Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05433337 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fibromyalgia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05433337's enrollment target sits among peer trials

60 41st of 76 higher than 32 of 76 other Fibromyalgia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05433337, the US trial registry maintained by the National Library of Medicine. NCT05433337 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.